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randomized to CZP at Wk0, 91% completed Wk24, 87% Wk48, and 80% Wk96. Rapid 
improvements observed to Wk24 were maintained to Wk96 for pain (Wk24 and 
Wk96; CFB: -28.5 and -31.3; MCID: 69.2% and 66.3%), fatigue (Wk24 and Wk96; CFB: 
-2.0 and -2.4; MCID: 64.1% and 60.4%), HAQ-DI (Wk24 and Wk96; CFB: -0.48 and 
-0.52; MCID: 48.7% and 48.0%), SF-36 PCS (Wk24 and Wk96; CFB: 8.01 and 9.01; MCID: 
67.4% and 60.1%), SF-36 MCS (Wk24 and Wk96; CFB: 4.50 and 3.92; MCID: 50.9% and 
43.6%), PsAQoL (Wk24 and Wk96; CFB: -3.87 and -4.50), and DLQI (Wk24 and Wk96; 
CFB: -5.8 and -6.0; MCID: 40.7% and 41.0%). Similar improvements were observed 
with both dosing regimens and in patients with or without prior anti-TNF exposure. 
Correlations were observed between improvements in PROs and DAS28 (data not 
shown). ConClusions: Improvements observed to Wk24 in generic and disease-
specific PROs were sustained to Wk96 of the RAPID-PsA trial for both CZP dosing 
regimens.
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objeCtives: Pain medication diaries have traditionally been collected via paper 
due to challenges of patients entering unlimited medications, units, dosages, and 
administration schedules. This study developed an electronic diary that permits site 
staff to enter medications that patients are taking, enables the patient to update 
medication taken and to enter new medications within the reporting period, and 
reduces the possibility of cheating behaviors during the study. Usability of this 
electronic diary was evaluated to ensure that patients in a clinical trial setting could 
successfully update their diaries in real-time to accurately track pain medication 
intake. Methods: A cross-sectional qualitative study was conducted involving 
usability interviews with patients diagnosed with osteoarthritis of the hip or knee 
who were taking pain medication. Interviews were conducted in two waves of 10 
participants each, allowing for evaluation of findings and revisions to the eDiary 
between waves. Results: Mean age of the sample (N= 20) was 66 years (range 
43-78), 90% over 60 years old; 60% were female; 95% were white; 70% completed 
secondary school or some college. In wave 1, issues were noted with training, select-
ing responses, exiting to send data, and some wording. For wave 2, the training 
module was revised to more closely match the diary, wording was revised, and a 
screen added to facilitate exiting the diary. No issues were noted with training, 4 
had trouble selecting responses, and 3 suggested additional instructions on the 
new screen. No additional changes were made following wave 2. ConClusions: 
The study showed it is possible to develop an electronic pain medication diary 
that allows patients to update their medications during a study. Extensive training 
was critical to the usability of the electronic version. The two wave study design 
provided the opportunity to detect and make changes to the eDiary with marked 
improvement in wave 2.
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objeCtives: Spondyloarthritis (SpA) is a group of diseases that share common clini-
cal, radiographic and genetic features. Axial SpA is one major subgroup including 
patients with radiographic (rad-axSpA) and non-radiographic axSpA (nr-axSpA). 
There has been limited research on axSpA patients in clinical practice and the 
impact of the disease on patient’s health-related quality of life (HrQoL). The aim 
of this study was to characterize patients with axSpA in clinical practice and to 
investigate similarities/differences between rad-axSpA and nr-axSpA with respect 
to their HrQoL. Methods: This is a longitudinal, multi-center cohort study where 
patients were consecutively recruited from Swedish clinical practice and followed 
for 3 months. At baseline, the rheumatologists registered information on disease 
history, extra articular manifestations and treatments. The patients answered 
online questionnaires capturing patient demographics, disease activity, function 
and HrQoL. HrQoL was measured using the EQ-5D and the Ankylosing Spondylitis 
Quality of Life Questionnaire (ASQoL). While higher scores in the EQ-5D indicate bet-
ter HrQoL, the opposite is true for the ASQoL. Results: 251 patients were included 
of whom 197 (78%) were classified as axial SpA. Of those, 125 (63%) were classi-
fied as rad-axSpA and 72 (37%) as nr-axSpA according to the ASAS axSpA criteria. 
There were more women in the nr-axSpA group (50%) compared with the rad-axSpA 
group (38%). The nr-axSpA patients had a shorter time between symptom onset and 
diagnosis than the rad-axSpA patients (6.7 vs. 9.0 years) and a significantly higher 
disease activity (BASDAI= 4.1 vs 2.7, p< 0.001). Mean EQ-5D score at baseline was 
0.66 for rad-axSpA and 0.61 for nr-axSpA, lower than the Swedish general popula-
tion (0.84). ASQoL scores was significantly higher in the nr-axSpA group (8.8 vs 6.4, 
p= 0.016). ConClusions: HRQoL is poorer in axial SpA patients compared to the 
general population and patients with nr-axSpA reported a higher impact on HRQoL 
than patients with rad-axSpA.
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objeCtives: Rheumatic diseases (RD) have been associated with functional and 
work-related disability due to the deliberating and progressive nature of these 
diseases and have many deleterious consequences on patients’ life. The aim of the 
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objeCtives: Despite widespread treatments for Osteoarthritis (OA), data on 
treatment patterns, adequacy of pain relief, and quality of life are limited. The 
prospective multinational Survey of Osteoarthritis Real World Therapies (SORT) 
was designed to investigate these aspects. This analysis aims to describe the clini-
cal characteristics and the patient reported outcomes of the Portuguese dataset 
of SORT baseline. Methods: The statistical analysis included, from January to 
December of 2011, 192 participants ≥ 50 years or older with primary knee OA 
from 7 health care centers in Portugal who were receiving oral or topic analgesics. 
Inadequate Pain Relief (IPR) was defined as a score > 4/10 in item 5 of the Brief Pain 
Inventory (BPI), indicating moderate to severe pain. Results: Overall, the median 
age was 67.0 ± 8.7 years and 77.6% were female. Mean duration of knee OA was 
6.3 ± 6.3 years. IPR was reported by 52.0% of the patients. The most prescribed 
analgesics were NSAIDs (88.1%), alternative therapies, including glucosamine, 
chondroitin and hyaluronate (44.3%) and paracetamol (28.6%). Patients with IPR 
scored higher than non-IPR patients in WOMAC – Stiffness (61.0 vs 39.7, p< 0.001) 
and WOMAC – physical function (59.2 vs 39.4, p< 0.001), meaning worse condi-
tion. Patients with IPR had worse quality of life related to knee osteoarthritis as 
measured by the SF-12 questionnaire (fair/poor: 86.9% vs. 72.0%, p< 0.001). 62.0% 
of patients with IPR were dissatisfied or very dissatisfied with the effects of anal-
gesics versus 34.0% of patients with non-IPR (p< 0.05). ConClusions: Despite the 
use of analgesics, over half of the Portuguese patients in SORT reported moderate 
to severe knee pain. Worse outcomes were also observed in this group regarding 
other symptoms of knee OA and general quality of life. These findings suggest 
that if an improvement of pain management in knee OA can be achieved, it may 
have high impact on patients’ lives.
PMS75
QUalitative eQUivalence betWeen a PaPer and electronic tablet 
verSion of the WoMac®nrS3.1 and Patient global aSSeSSMent
Eremenco S.1, Fleming S.2, Riordan D.3, Stringer S.1, Gleeson S.1, Sanga P.4, Kelly K.5
1Evidera, Inc., Bethesda, MD, USA, 2Janssen Global Services, Titusville, NJ, USA, 3Janssen Research 
and Development, Raritan, NJ, USA, 4Janssen Research and Development, Titusville, NJ, USA, 
5Janssen Research and Development L.L.C., Titusville, NJ, USA
objeCtives: Prior equivalence work with the WOMAC® scale was published for 
the VAS scale and older touchscreen computer technology. Additional equivalence 
evaluation of the WOMAC®NRS3.1 and the Patient Global Assessment (PGA) in a 
newer tablet with stylus was needed to document suitability of this mode of data 
collection for these instruments in upcoming clinical trials. Methods: A cross-sec-
tional qualitative study was conducted involving cognitive and usability interviews 
with patients diagnosed with osteoarthritis of the hip or knee who were taking 
pain medication for their condition. Interviews were conducted in two waves of 10 
participants each, with revisions to the PGA made in between the rounds, which 
allowed for changes to the electronic version to be evaluated. Results: Mean age 
of the sample (N= 20) was 66 years, (range 43-78), 90% over 60 years old; 60% were 
female; 95% were white; 75% were retired; 70% had completed secondary school or 
some college, while 30% had completed college or a post-graduate degree. In wave 
1, minor issues were found with completing the WOMAC®, mainly with using the 
stylus to select responses and glare on the screen. There were no issues identified 
in interpreting the response scale. For the PGA, 50% (5/10) used the wrong recall 
period (48 hours or longer). The PGA recall period was revised from “at this time” 
to “over the past 24 hours” and bolded for emphasis. In wave 2, similar issues with 
glare and stylus response were found, while 80% used the correct recall period on 
the PGA, with 20% using 48 hours. ConClusions: The study showed excellent 
qualitative equivalence between the paper and electronic WOMAC® with only minor 
usability issues. The two wave study design provided the opportunity to detect and 
make changes to the PGA recall period and formatting that showed improvement 
in the second wave.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 96 
weeks (wks) of the RAPID-PsA trial. Methods: The RAPID-PsA trial (NCT01087788) 
is double-blind and placebo-controlled to Wk24, dose-blind to Wk48 and open-label 
to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally ran-
domized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wk0, 
Wk2, Wk4) continued on their assigned dose in the dose-blind phase and OLE. Here 
we present PRO data for the CZP-treated randomized set, including mean change 
from baseline (CFB) and Minimal Clinically Important Differences (MCIDs). Data 
were also analysed for CZP-randomized patients with (19.8%) or without (80.2%) 
prior anti-TNF exposure. Missing data were imputed by LOCF. Correlations between 
clinical outcomes and PROs were also investigated. Results: Of 273 patients 
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objeCtives: It is estimated that 30% of psoriasis (PSO) patients also develops pso-
riatic arthritis (PSA). This potential disease evolution brings along new symptoms 
such as swollen and painful joints and mobility problems. Since both diseases are 
potentially degenerative, the aim of this study was to measure which group of 
patients (PSO or PSA) is willing to pay most out of pocket to avoid their health related 
quality of life (HRQoL) to worsen. Methods: 395 US patients diagnosed with either 
psoriasis (n= 151) or psoriatic arthritis (n= 247) completed a questionnaire as part of 
a broader survey of treatment of PSO/PSA. The questionnaire included the EQ-5D-5L 
instrument and accompanying VAS. Patients were additionally asked to indicate by 
reference to the EQ-5D VAS scale the amount of money per month they would be 
willing to pay for treatments that would prevent a decline in HRQoL by 10 points. 
Price sensitivity curves were created by means of linear regression analysis that 
predict the proportion of patients willing to pay a certain amount of $ out of pocket 
per month. Results: For both PSO (R² = 0,82) and PSA (R² = 0,86) monthly cost out of 
pocket (x-variable) was a good predictor of the proportion of patients that is willing 
to pay a certain amount out of pocket per month (y-variable). Regression models 
look as follows. For PSO: y = 0,77e-0,005x for PSA: y = 0,86e-0,007x. To give a specific 
example 42% of the PSA patients is willing to pay $100 per month out of pocket 
whereas this is 47% among PSO patients. ConClusions: PSO patients are prepared 
to pay more out of pocket on a monthly basis to avoid their HRQoL to worsen than 
PSA patients. Further research is required to understand what drives this difference.
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objeCtives: To report the long-term effect of certolizumab pegol (CZP) on work-
place and household productivity up to 96 weeks (wks) in patients with axial 
spondyloarthritis (axSpA), including ankylosing spondylitis (AS, meeting modi-
fied New York criteria) and non-radiographic axSpA (nr-axSpA). Methods: The 
ongoing RAPID-axSpA trial (NCT01087762), is double-blind and PBO-controlled to 
Wk24, dose-blind to Wk48 and open-label to Wk204. Patients had active axSpA, 
according to ASAS criteria, including AS and nr-axSpA patients. Patients originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] 
at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients enter-
ing dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W 
or CZP 400mg Q4W after Wk24 or, for non-responders, after Wk16. The validated 
arthritis-specific Work Productivity Survey (WPS; administered Q4W) assessed the 
impact of axSpA on workplace and household productivity. WPS responses (LOCF 
imputation) in patients originally randomized to CZP are summarized descriptively 
over 96 wks. Results: 325 patients were randomized, of whom 218 received CZP 
(200mg Q2W or 400mg Q4W) from Wk0. Of patients randomized to CZP at baseline 
(BL), 93% completed Wk24, 88% Wk48 and 80% Wk96. At BL, 72% of CZP patients 
were employed outside of the home. Employed CZP patients reported reductions 
in workplace absenteeism and presenteeism to Wk24, with continued improve-
ments to Wk96 (BL: mean 1.8 days missed/month, mean 5.2 days with reduced 
productivity/month vs Wk96: mean 0.6 days missed/month, mean 1.4 days with 
reduced productivity/month). CZP patients also reported continued improvements 
in household productivity and social participation to Wk96 in both dose regimens, 
and similar improvements were observed in AS and nr-axSpA. ConClusions: 
The initial improvements with CZP in workplace and household productivity and 
increased participation in social/leisure activities were continued to Wk96 in axSpA, 
AS and nr-axSpA patients.
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objeCtives: To examine the long-term effect of certolizumab pegol (CZP) on 
workplace and household productivity up to 96 weeks (wks) in patients with active 
psoriatic arthritis (PsA). Methods: The ongoing RAPID-PsA trial (NCT01087788) 
is double-blind and PBO-controlled to Wk24, dose-blind to Wk48 and open-label 
to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] 
at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients entering 
dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W or 
400mg Q4W after Wk24 or, for non-responders, Wk16. The validated arthritis-spe-
cific Work Productivity Survey (WPS) administered Q4W from baseline (BL), assessed 
the impact of PsA on workplace and household productivity in the randomized set. 
WPS responses (LOCF imputation) in patients originally randomized to CZP groups 
are summarized descriptively over 96 wks. Results: 409 patients were randomized, 
of whom 273 received CZP 200mg Q2W or CZP 400mg Q4W. Of patients randomized 
to CZP, 91% completed Wk24, 87% Wk48 and 80% Wk96. In employed patients in both 
CZP groups (60.8% of all CZP patients at BL), decreases in absenteeism and pres-
enteeism to Wk24 were continued up to Wk96 (BL: mean 2.0 and 1.6 days missed/
month in the CZP 200mg Q2W and 400mg Q4W groups, respectively; mean 5.2 and 
5.1 days with reduced productivity/month vs Wk96: mean 0.3 and 0.4 days missed/
month; mean 0.7 and 1.5 days with reduced productivity/month). Improvements in 
household productivity and social participation reported in both CZP groups over 
24 wks were also maintained to Wk96. ConClusions: The initial improvements 
present study was to measure the functional status and quality of life in RD patients receiving 
the biologic agent golimumab in Greece Methods: A descriptive study was conducted 
estimating the annual Quality-of-Life (QoL) improvement for 148 patients diagnosed 
with rheumatoid arthritis (RA), psoriatic arthritis (PS) and ankylosing spondylitis 
(AS). QoL was estimated with standardized questionnaires such as EQ-5D and HAQ 
questionnaire. In addition, twenty specific parameters including “general health”, 
“severity of pain”, “productivity level” etcetera wereassessed on 10-point Likert scale. 
Data was collected by doctors across the country at 3 month intervals (4 waves of 
questionnaires during the year). Results: Patients with RA reported improved QoL 
by 14%, followed by 0.67 decrease of average HAQ score. They also reported a 7.5 hours 
gain of working hours and an overall 14% gain in productivity per week. Patients with 
AS were estimated to present 30% improvement in general health condition according 
to their doctors with similar self-reported estimations. Additionally, their QoL was 
improved by 17%. Similarly, patients with PS estimated their QoL improved by 17% 
with a 6hr/week gain in working hours otherwise missed, while the average HAQ score 
fell by 0.71 Findings are in accordance with similar published studies all contributing 
to the general assumption that patients receiving biological agents experience greater 
QoL improvement compared to conservative treatment options. ConClusions: 
Statistical analysis revealed significant improvement of functional status, quality of 
life, productivity gains and decrease of disease activity for those receiving Golimumab 
in Greece for all three disease groups. Amongst limitations, both number of the study 
group and follow-up period should be taken into consideration.
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objeCtives: The current prevalence of Chronic Lumbosciatic Syndrome (CLSS) in 
Slovakia ranges in about 170000 cases. The CLSS has a great impact on quality 
of life (QoL) and the ability to work too. Till now in Slovakia was not realised the 
study like this. Methods: 86 patients with CLSS were studied. The “hospital” and 
the “out-patients clinic” group had 43 vs 43 patients. The average age was 50.36 vs 
51.79 y., weight – 61.04 vs 77.95 kg, duration of illness – 5.3 vs 5.0 years, symptoms 
of illness before diagnosis – 2.27 vs 2.16 years. QoL and the ability to work was 
evaluated on the numeric scale from 0 to 10 (0 for the worst, 10 for the best) by 
patients themselves. Results: The “hospital” and the “out-patients clinic” group 
had these results: the average of hospitalisation – 1.51 vs 1.44 times, incapacity to 
work – 3.06 vs 2.90 months. QoL in the time of good health was 8.2 vs 8.04, in the 
time of diagnosis – 5.86 vs 6.74, and in the current time – 4.58 vs 3.95. The work 
ability (WA) had these results: WA in time of good health was 8.97 vs 9.04 in the 
time of diagnosis – 8.16 vs 8.13, and in the current time – 3.83 vs 3.83. The impact 
of the treatment on the QoL was 5.37 vs 6.06 and on the patients families QoL it 
was 6.16 vs 6.13. The willingness to pay for the perfect cure was 477.90 € vs 524.41 € 
per month (the average salary in Slovakia in 2013 was 824 € ). ConClusions: CLSS 
has a great impact on QoL and on the WA too. There was not statistical difference 
between both “hospital and out-patient clinic” patients in the QoL and WA. Early 
diagnosis is important to effective treatment.
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objeCtives: For patients with rheumatoid arthritis (RA) and inadequate response 
to traditional therapy, treatment with biologics is recommended to reduce dis-
ease progression and improve HRQol. Nevertheless, up to 30% of patients stop 
treatment on their own initiative. Aim of the study is to develop and validate an 
instrument to assess reasons for treatment discontinuation of biologics in patients 
with RA. Methods: We conducted expert interviews with rheumatologists (n= 5) 
to develop a questioning route, which was used in 2 focus groups with a total of 
15 RA patients who dropped out therapy (phase 1). Based on these results a draft 
questionnaire was developed and pre-tested (phase 2; n= 6), resulting in the pilot 
questionnaire. In the validation phase (phase 3) the questionnaire is completed by 
approx. 200 patients, with an interim analysis planned after recruitment of half 
the sample size. Quantitative data analyses will focus on psychometric proper-
ties: missing data, floor/ceiling effects, factorial validity, distribution of properties. 
Patients are recruited at 40 German office based rheumatologists, with 5 patients 
per center. Results: The final questionnaire consists of 82 items covering socio-
demographic aspects, HRQoL, history of treatment and disease, treatment infor-
mation, expectations and satisfaction and ”reasons for discontinuation”. Piloting 
showed that HRQoL, treatment and working-life aspects have impact on treatment 
discontinuation. Particularly, information about treatment options, patient-doctor 
relationship and financial burden were addressed. The questionnaire has proven 
to be feasible in field-test. Validation phase is currently ongoing; results from the 
interim analysis will be presented. ConClusions: Interviews with experts and 
patients demonstrated that treatment discontinuation is triggered by multiple rea-
sons. A targeted developed questionnaire is necessary to identify latent reasons for 
treatment discontinuation. Furthermore, an “easy-to-use” questionnaire could be 
used in daily routine to identify patients likely to withdraw treatment and need 
special patient adherence programs.This research was funded by Pfizer GmbH.
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